Industry Overview - The Chinese clinical CRO industry is entering a recovery and stable growth phase, transitioning from an offshore outsourcing model to a global contributor of innovative assets over the past decade [2][13] - The industry experienced a growth phase from 2017-2019 and a rapid development period from 2020-2022, with a forecasted compound annual growth rate (CAGR) of over 12% from 2025 to 2028, expecting to exceed 75 billion RMB by 2028 [2][13] - As of December 2025, the average number of clinical trial projects undertaken by each clinical CRO in China increased by 20.6% year-on-year, reaching 42.9 projects, narrowing the gap with the U.S. [5][16] Investment Trends - The investment from multinational pharmaceutical companies in China's clinical trials remains stable, with 25%-30% of Phase III innovative drug trials initiated by these companies over the past eight years [6][17] - Local pharmaceutical companies are also actively investing in innovative drug clinical research, contributing 15%-20% of Phase III trials in China during the same period [6][17] - The financing channels for Chinese innovative drugs have diversified, with a significant increase in licensing and mergers and acquisitions (M&A) transactions, totaling 178 deals in 2024-2025 [9][20] Company Highlights - Tigermed has ranked first in market share in China's clinical CRO sector for several years, with a compound annual growth rate of 14.8% in new orders from 2019 to 2024, surpassing the market's growth rate of 12.5% [11][23] - The average price of domestic clinical trial services is stabilizing after fluctuations in 2022-2023, indicating strong business continuity and resilience [11][23] - In 2025, Tigermed aims for sustainable development, achieving an AAA rating in MSCI ESG, and enhancing its service capabilities through the acquisition of CRO company Micron [11][23] - The company is investing in AI applications and platforms, launching an AI medical translation platform and an AI medical writing platform in 2025 [11][23]

Economic Overview - The GDP growth for Q4 2025 is reported at 4.5%, matching expectations but down from 4.8% in the previous quarter. December retail sales growth is at 0.9%, below the expected 1.5% and previous 1.3% [12][12] - Fixed asset investment shows a cumulative year-on-year decline of 3.8%, worse than the expected decline of 2.4% and previous 2.6%. Real estate development investment has a cumulative decline of 17.2% compared to the previous 15.9% [12][12] - Industrial value-added growth for December is reported at 5.2%, exceeding the expected 4.9% and previous 4.8% [12][12] Key Changes in Economic Structure - Three significant changes are identified: improvement in service consumption, easing of the "crowding out effect" from debt reduction, and recovery in new economic sectors [12][12] - The shift in consumption policies from goods to services is noted, with service retail growth increasing while traditional retail indicators decline [12][12] - Investment slowdown is attributed to intensified corporate debt repayment policies, which ultimately benefit cash flow recovery for companies [12][12] Sector Performance - The electric grid equipment sector shows a significant increase of 60.88% over the past six months, with a daily increase of 7.01% [1] - The digital media sector has seen a decline of 4.34% yesterday, with a 21.93% increase over the past month [1] - The hotel and catering industry has increased by 3.87% yesterday and 20.46% over the past six months, indicating resilience in service consumption [1] Investment Opportunities - The report highlights potential investment opportunities in sectors benefiting from service consumption recovery and easing debt repayment pressures [12][12] - Companies in the PCB drilling needle industry are noted for their growth potential, driven by increasing demand in emerging markets [20][20] - The report suggests focusing on companies with strong cash flow recovery and those positioned in high-growth sectors such as healthcare and technology [12][12][20]

Investment Rating - The report maintains an "Outperform" rating for several companies, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [6][7]. Core Insights - The annual J.P. Morgan Healthcare Conference concluded successfully, with positive information from global pharmaceutical companies, including new pipeline disclosures and major deals. The report highlights the high prosperity in the innovative drug sector and recommends continuous investment in innovative drugs and the industry chain [25][26]. - The A-Shares pharmaceutical sector underperformed the market in the third week of January 2026, with the Shanghai Composite Index falling by 0.4% and the SW Pharmaceutical and Biological sector declining by 0.7% [8][27]. - The Hong Kong stock pharmaceutical sector performed in line with the market, while the U.S. pharmaceutical sector underperformed. The Hang Seng Healthcare index increased by 2.4%, and the S&P 500 Healthcare Select Sector decreased by 1.1% [28]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the high prosperity of innovative drugs and maintains overweight ratings for key pharmaceutical companies. It also recommends Biopharma/Biotech companies with promising pipelines and volume increases, as well as CXO and upstream companies benefiting from innovation [6][25]. Section 2: A-Shares Pharmaceutical Sector Performance - In the third week of January 2026, the A-Shares pharmaceutical sector's performance was ranked 17th among Shenwan primary industries, with a decline of 0.7%. The medical service sub-sector showed a positive performance of +3.3% [8][12][27]. Section 3: Hong Kong and U.S. Pharmaceutical Sector Performance - The Hong Kong pharmaceutical sector performed similarly to the market, while the U.S. sector underperformed. Notable gainers in the U.S. included MODERNA (+22%) and QUEST DIAGNOSTICS (+9%), while major decliners included BIOGEN (-12%) and BOSTON SCIENTIFIC (-10%) [28].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [2]. Core Insights - The report highlights the ongoing performance of the pharmaceutical sector, with a focus on the upcoming annual earnings forecasts and the potential for exceeding expectations. The sector has shown a return of 7.08% since the beginning of 2026, outperforming the CSI 300 index by 4.88% [8][12]. - Key catalysts in the industry include significant partnerships and acquisitions, such as AbbVie’s $6.5 billion upfront payment for RC148 and a $1 billion collaboration between Eli Lilly and NVIDIA to accelerate AI drug development [4][10]. - The report emphasizes the importance of innovative drug chains and the AI+ theme, suggesting that these areas will continue to attract investment and yield positive results [4][5]. Summary by Sections Industry Overview - The pharmaceutical sector's total market capitalization is approximately 74,744.70 billion yuan, with a circulating market value of 68,522.64 billion yuan [2]. - The report notes that the pharmaceutical sector is currently valued at 23.4 times PE based on 2026 earnings forecasts, which is a premium of 13.7% compared to the overall A-share market [15]. Market Dynamics - The report indicates that the pharmaceutical sector has experienced a mixed performance, with medical services up by 3.29% while other segments like medical devices and traditional Chinese medicine have seen declines [8][12]. - The report also mentions that the market is transitioning to a more rational and steady growth phase, moving away from the initial volatility seen at the start of the year [4]. Key Company Performances - Notable companies such as WuXi Biologics, Sangamo Therapeutics, and Tigermed have been highlighted for their strong performance, with WuXi Biologics showing a significant increase of 26.53% in January [24]. - The report suggests continued monitoring of companies involved in AI and small nucleic acid technologies, as they are expected to lead future growth in the sector [5][9]. Investment Recommendations - The report recommends focusing on companies that are well-positioned within the innovative drug chain and AI+ sectors, as these are anticipated to provide substantial returns [4][5]. - Specific stocks recommended include WuXi Biologics, Sangamo Therapeutics, and Tigermed, which have shown promising growth trajectories [24].

Market Overview - The Hong Kong stock market opened lower on January 19, with the Hang Seng Index at 26,641.60 points, down 203.36 points, a decline of 0.76% [1] - The Hang Seng Tech Index opened at 5,777.07 points, down 45.11 points, a decrease of 0.77% [4] Airline Sector Performance - Airline stocks showed resilience, with China Eastern Airlines (HK00670) rising over 6%, and both China Southern Airlines (HK01055) and Air China (HK00753) increasing by more than 2% [3] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 7.61% and a seat load factor of 85.65%, up 2.14 percentage points [6] - China Southern Airlines announced an 11.89% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 11.20% and a seat load factor of 84.05%, down 0.53 percentage points [7] - Air China reported a 4.0% year-on-year increase in passenger capacity for December 2025, with passenger turnover up 10.0% and a seat load factor of 82.2%, up 4.5 percentage points [7] Other Sector Movements - The technology sector saw widespread declines, with Bilibili dropping over 4%, Alibaba and Kuaishou down over 2%, and Xiaomi and Meituan down over 1% [7] - The metals sector was active, with Zijin Mining opening over 1% higher [7] - The lithium battery sector experienced mostly gains, with BYD rising over 1% [7] - The domestic real estate sector faced declines, with Country Garden falling over 10% [7] - The biopharmaceutical sector opened lower, with Tigermed down over 2% [7] Economic Outlook - According to Galaxy Securities, the U.S. CPI for December 2025 rose 2.7% year-on-year, with core CPI up 2.6%, both in line with previous values [8] - The U.S. PPI for November increased by 3%, exceeding the forecast of 2.7% [8] - Initial jobless claims in the U.S. decreased by 9,000 to 198,000, significantly below the market expectation of 215,000, marking the lowest level since November of the previous year [8] - China's foreign trade in 2025 reached 45.47 trillion yuan, a year-on-year growth of 3.8%, marking nine consecutive years of growth [8] - The M2-M1 spread at the end of December 2025 was 4.7 percentage points, widening from the previous month's 3.1 percentage points [8] Investment Recommendations - The technology sector remains a long-term investment focus, benefiting from price increases in the supply chain, domestic substitution, and accelerated AI applications [8] - The consumer sector is expected to continue benefiting from policy support, with attention needed on policy implementation and improvements in consumption data [8] - Given the escalating geopolitical tensions, precious metals and other safe-haven assets are likely to benefit [8]

Market Overview - The Hong Kong stock market opened slightly lower on January 19, with the Hang Seng Index down 0.76% at 26,641.6 points, the Hang Seng Tech Index down 0.77% at 5,777.07 points, the State-Owned Enterprises Index down 0.76% at 9,151.07 points, and the Red Chip Index down 0.4% at 4,122.65 points [1] - Major tech stocks experienced declines, including Alibaba down 2.53%, Tencent down 0.65%, JD.com down 0.53%, Xiaomi down 1.29%, NetEase down 0.83%, Meituan down 1.2%, Kuaishou down 1.53%, and Bilibili down 2.69% [1] - The non-ferrous metals sector was active, with Zijin Mining rising over 3%, while the lithium battery sector saw most stocks increase, with BYD rising over 1% [1] - Some domestic property stocks fell, with Country Garden down over 10%, and the biopharmaceutical sector opened lower, with Tigermed down over 2% [1] Company News - China Shenhua (01088.HK) expects coal sales volume in 2025 to be 431 million tons, a year-on-year decrease of 6.4% [2] - New China Life Insurance (01336.HK) anticipates cumulative original insurance premium income in 2025 to reach 195.899 billion yuan, a year-on-year increase of 15% [3] - Yongjia Group (03322.HK) projects a revenue growth rate of approximately 16% for its high-end fashion retail business in the fourth quarter of 2025 [4] - Ronshine China (03301.HK) expects total contract sales in 2025 to be approximately 3.777 billion yuan, a year-on-year decrease of 50.96% [5] - Tianhong International Group (02678.HK) issued a profit warning, expecting a net profit increase of about 60% for the 2025 fiscal year due to a recovery in domestic and international market orders [5] - Qizhi Group (00917.HK) anticipates turning a profit in 2025, with net profit estimated between 270 million to 330 million yuan, compared to a loss of 1.663 billion yuan in the previous year [5] - October Rice Field (09676.HK) issued a profit warning, expecting adjusted net profit of approximately 550 million to 590 million yuan in 2025, a year-on-year increase of about 57.6% to 69.1% [5] - China Boton (03318.HK) issued a profit warning, expecting goodwill impairment losses of no less than approximately 750 million yuan for its tobacco flavor business in 2025 [5] Strategic Insights - Guojin Securities suggests that the Hong Kong stock market is entering a "spring market" at the beginning of 2026, likely to continue until mid-year, driven by domestic and international easing expectations and policy collaboration [9] - Galaxy Securities anticipates narrow fluctuations in the Hong Kong stock market due to reduced short-term interest rate cut expectations from the Federal Reserve and increased global geopolitical uncertainties [9] - GF Securities views the chemical industry as a typical cyclical sector, predicting a "dawn" phase for the chemical industry amid capital expenditure growth turning negative and a focus on domestic demand expansion [9]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [6][26]. Core Insights - The report emphasizes the continuous recommendation of innovative pharmaceuticals and medical devices, highlighting the high growth potential in the sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also recommends Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][3]. Summary by Sections 1. Continuous Recommendation of Innovative Pharmaceuticals and Medical Devices - The report highlights the high growth potential of innovative drugs and recommends several companies for investment, including Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical. It also suggests Biopharma/Biotech companies like Kelun Biotech, BeiGene, and others, as well as CXO and upstream pharmaceutical companies [6][7]. 2. A-share Pharmaceutical Sector Performance - In the third week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the Shanghai Composite Index declining by 0.4% and the SW Pharmaceutical and Biotech index falling by 0.7% [8][11]. 3. Hong Kong and US Market Performance - The Hong Kong pharmaceutical sector performed in line with the market, while the US pharmaceutical sector underperformed. In the same week, the Hang Seng Healthcare index rose by 2.4%, and the S&P 500 healthcare sector fell by 1.1% [19][20].

Core Insights - The top three companies with the highest short positions as of January 9 are Vanke Enterprises (02202), Dongfang Electric (01072), and COSCO Shipping Holdings (01919), with short ratios of 18.74%, 17.39%, and 16.49% respectively [1][2] - The companies with the largest absolute increase in short positions are Goldwind Technology (02208), Zhaoyan New Drug (06127), and Jingtai Holdings (02228), with increases of 6.84%, 2.14%, and 1.85% respectively [1][2] - The companies with the largest absolute decrease in short positions are COSCO Shipping Energy (01138), Sanhua Intelligent Control (02050), and Huahong Semiconductor (01347), with decreases of -1.77%, -0.80%, and -0.71% respectively [1][3] Top 10 Short Positions - Vanke Enterprises (02202) has a short position of 413 million shares, representing a short ratio of 18.74% [2] - Dongfang Electric (01072) has a short position of 70.93 million shares, with a short ratio of 17.39% [2] - COSCO Shipping Holdings (01919) has a short position of 475 million shares, with a short ratio of 16.49% [2] - Other notable companies in the top 10 include Heng Rui Medicine (01276) at 15.19% and Ping An Insurance (02318) at 14.74% [2] Largest Increases in Short Positions - Goldwind Technology (02208) saw its short ratio increase from 4.35% to 11.18%, an increase of 6.84% [2] - Zhaoyan New Drug (06127) increased from 6.65% to 8.79%, an increase of 2.14% [2] - Jingtai Holdings (02228) increased from 3.34% to 5.19%, an increase of 1.85% [2] Largest Decreases in Short Positions - COSCO Shipping Energy (01138) decreased from 7.11% to 5.34%, a decrease of -1.77% [3] - Sanhua Intelligent Control (02050) decreased from 6.52% to 5.72%, a decrease of -0.80% [3] - Huahong Semiconductor (01347) decreased from 4.85% to 4.13%, a decrease of -0.71% [3]

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Junda Co. leading in premium rates, while CATL, Heng Rui Medicine, and China Merchants Bank are at the bottom of the list [1] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 800.00% with a deviation value of -61.15% [1] - Zhejiang Shibao (01057) has a premium rate of 407.30% with a deviation value of 42.48% [1] - Junda Co. (02865) has a premium rate of 329.76% with a deviation value of 109.58% [1] - Other notable companies include Hongye Futures (03678) with a premium rate of 264.62% and Sinopec Oilfield Service (01033) with a premium rate of 264.47% [1] Group 2: Bottom AH Share Premium Rates - CATL (03750) has a premium rate of -12.92% with a deviation value of -1.93% [1] - Heng Rui Medicine (01276) has a premium rate of -3.34% with a deviation value of -4.08% [1] - China Merchants Bank (03968) has a premium rate of -1.62% with a deviation value of 0.25% [1] - Other companies with low premium rates include Wu Chai Power (02338) with a premium rate of 6.54% and Midea Group (00300) with a premium rate of 7.80% [1] Group 3: Top AH Share Deviation Values - Junda Co. (02865) leads with a deviation value of 109.58% [1] - Zhejiang Shibao (01057) follows with a deviation value of 42.48% [1] - Goldwind Technology (02208) has a deviation value of 41.46% [1] - Other companies with significant deviation values include Jinju Group (02009) with 22.71% and Guanghetong (00638) with 17.96% [1] Group 4: Bottom AH Share Deviation Values - Northeast Electric (00042) has the lowest deviation value at -61.15% [1] - Nanhua Futures (02691) follows with -40.56% [1] - Chenming Paper (01812) has a deviation value of -23.42% [1] - Other companies with negative deviation values include Jinli Permanent Magnet (06680) at -17.16% and Guolian Minsheng (01456) at -15.36% [1]

Investment Rating - The investment rating for WuXi AppTec (2268 HK) is maintained at "Buy" with a target price of HKD 82.24 [8][14]. Core Insights - WuXi AppTec is expected to see significant revenue growth in 2025, with revenue, gross profit, net profit, and adjusted net profit projected to increase by over 45%, 70%, 38%, and 65% year-on-year, respectively [1][2]. - The company plans to acquire Dongyao Pharmaceutical for approximately HKD 3.09 billion, which is anticipated to enhance its competitive edge and capacity [5][6]. - The demand for Contract Research, Development, and Manufacturing Organization (CRDMO) services is expected to rise as global Antibody-Drug Conjugate (ADC) pipelines commercialize [1][3]. Revenue and Profit Forecast - Revenue for 2025 is estimated at approximately HKD 59.6 billion, with a gross profit of HKD 21.1 billion and a net profit of HKD 14.7 billion [2][12]. - The gross margin is projected to be around 35.4%, an increase of about 5 percentage points from 2024, indicating strong operational efficiency [2][12]. - Adjusted net profit is expected to grow by over 65% for the year, despite a decline in profit margins in the second half of 2025 due to foreign exchange impacts and rising expense ratios [2][12]. Project Pipeline - The company signed 70 new iCMC projects in 2025, with 22 being molecular projects, contributing to a total of 252 iCMC projects [3]. - WuXi AppTec is expected to lead in the development of new conjugated molecules, with over half of the new projects being innovative types [3]. - The global market share is projected to increase from 21.7% in 2024 to over 24% in 2025 [3]. Capacity Expansion - The company is expanding its production capacity, with existing DP capacity in Wuxi being maintained and expanded in 2025 [4]. - New production facilities in Singapore are expected to be operational by mid-2025, with additional overseas capacity coming online in 2026 [4]. - The acquisition of the Hefei base is expected to enhance peptide development and production capabilities, with an annual capacity exceeding 40 kg [4]. Acquisition of Dongyao - The acquisition of Dongyao Pharmaceutical is expected to strengthen WuXi AppTec's existing competitive position, as Dongyao has significant production capabilities and a strong client base [5][6]. - Dongyao operates two antibody bulk production lines and three independent ADC bulk production workshops, which will complement WuXi AppTec's offerings [5]. Earnings Forecast and Valuation - Adjusted net profit forecasts for 2025, 2026, and 2027 are revised to HKD 15.9 billion, HKD 22.4 billion, and HKD 31.6 billion, respectively, reflecting a CAGR of 39% [6][12]. - The target price is based on a PEG ratio of 1.06x for 2026, aligning with comparable companies in the sector [6][14].